methylphenidate has been researched along with Learning Disabilities in 81 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Learning Disabilities: Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether children with attention-deficit hyperactivity disorder (ADHD) and learning disabilities respond differently to methylphenidate (MPH) compared with children with ADHD only." | 9.12 | Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial. ( Bhat, M; Grizenko, N; Joober, R; Schwartz, G; Ter-Stepanian, M, 2006) |
| "To establish the efficacy and safety of methylphenidate (MPH) treatment for attention deficit hyperactivity disorder (ADHD) in a group of children and young people with learning disability and severe epilepsy." | 8.89 | Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. ( Aylett, SE; Fosi, T; Lax-Pericall, MT; Neville, BG; Scott, RC, 2013) |
| "Methylphenidate was instrumental in improving performance on many psychological tests, but did not affect performance on standardized achievement tests." | 6.64 | Methylphenidate effects in learning disabilities. Psychometric changes. ( Gittleman-Klein, R; Klein, DF, 1976) |
| "To determine whether children with attention-deficit hyperactivity disorder (ADHD) and learning disabilities respond differently to methylphenidate (MPH) compared with children with ADHD only." | 5.12 | Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial. ( Bhat, M; Grizenko, N; Joober, R; Schwartz, G; Ter-Stepanian, M, 2006) |
| " The three groups were found to be similar in mean age, gender ratio, prevalence, and pattern of associated learning disabilities, family history of psychopathology, and probability of favorable response to methylphenidate." | 5.07 | Attention deficit disorder in children: three clinical variants. ( de Quirós, GB; Kinsbourne, M; Palmer, RL; Rufo, DT, 1994) |
| "To establish the efficacy and safety of methylphenidate (MPH) treatment for attention deficit hyperactivity disorder (ADHD) in a group of children and young people with learning disability and severe epilepsy." | 4.89 | Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. ( Aylett, SE; Fosi, T; Lax-Pericall, MT; Neville, BG; Scott, RC, 2013) |
| " Withdrawal of the narcolepsy treatment and initiation of haloperidol 1 mg/day (the only antipsychotic treatment she could tolerate) improved the delusions, hallucinations and dysphoria but worsened the narcolepsy symptoms." | 3.85 | Narcolepsy-cataplexy and psychosis: a case study. ( Arango-Lopez, C; Canellas-Dols, F; Delgado, C; Peraita-Adrados, R, 2017) |
| " These cases were selected from a prior quantitative study in which three antihistamines (meclizine, cyclizine, dimenhydrinate) and three stimulants (pemoline, methylphenidate, dextroamphetamine) were tested in variable combinations (using a specific clinical method) for favorable responses by 100 children characterized by diagnostic evidence of learning disabilities and cerebellar-vestibular dysfunctioning." | 3.68 | Dramatic favorable responses of children with learning disabilities or dyslexia and attention deficit disorder to antimotion sickness medications: four case reports. ( Levinson, HN, 1991) |
| " Both interventions proved effective for improving neurocognitive test performance and behavior, although broad-band ratings revealed dose-response curves different from those obtained from the neurocognitive tests." | 2.68 | Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention-deficit/hyperactivity disorder. ( Denney, C; Goya, S; Isaacs, P; Loo, S; Rapport, MD; Scanlan, S, 1996) |
| "Attention deficit (ADDH) children self-paced the delivery of response pairs for paired-associate learning at about the rate previously shown to be conducive to relatively good learning in attention deficit." | 2.66 | Self-paced learning in children with attention deficit disorder with hyperactivity. ( Dalby, JT; Kinsbourne, M; Swanson, JM, 1989) |
| " The clinically titrated methylphenidate dosage levels for the subjects were related both to the augmenter-reducer classification and to pretreatment HR levels; that is, subjects who were ERP reducers and/or had higher HR levels, especially under reward conditions, were blindly titrated at higher levels than those who were augmenters and/or had lower HR levels." | 2.65 | Effects of reward and methylphenidate on heart rate response morphology of augmenting and reducing children. ( Ackerman, PT; Dykman, RA; Holcomb, PJ, 1984) |
| "Four groups of children referred for attention disorders, learning disorders, or both were blindly titrated at statistically equivalent dosage levels of methylphenidate and improved more or less equivalently on several measures of attentiveness (cognitive style tests and reaction time)." | 2.65 | Methylphenidate effects on cognitive style and reaction time in four groups of children. ( Ackerman, PT; Dykman, RA; Holcomb, PJ; McCray, DS, 1982) |
| "Methylphenidate was instrumental in improving performance on many psychological tests, but did not affect performance on standardized achievement tests." | 2.64 | Methylphenidate effects in learning disabilities. Psychometric changes. ( Gittleman-Klein, R; Klein, DF, 1976) |
| "Children with Fetal Alcohol Spectrum Disorders (FASD) may have significant neurobehavioural problems persisting into adulthood." | 2.45 | Systematic review of interventions for children with Fetal Alcohol Spectrum Disorders. ( Bower, C; Elliott, EJ; Peadon, E; Rhys-Jones, B, 2009) |
| "Thus, overnutrition due to fats may be central to childhood psychological perturbations such as anxiety and ADHD." | 1.39 | Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice. ( Chiu, GS; Freund, GG; Gainey, SJ; Kaczmarczyk, MM; Kelley, KW; Kwakwa, KA; Lawson, MA; Machaj, AS; Martin, SA; Meling, DD; Miller, MJ; Newman, AF; Wang, Y; Woods, JA; York, JM, 2013) |
| "Minimal brain dysfunction is a neurodevelopmental disorder which can be found in nearly 20% of school children." | 1.26 | Minimal brain dysfunction/specific learning disability: a clinical approach for the primary physician. ( Levy, HB, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 46 (56.79) | 18.7374 |
| 1990's | 9 (11.11) | 18.2507 |
| 2000's | 17 (20.99) | 29.6817 |
| 2010's | 9 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canellas-Dols, F | 1 |
| Delgado, C | 1 |
| Arango-Lopez, C | 1 |
| Peraita-Adrados, R | 1 |
| Kaczmarczyk, MM | 1 |
| Machaj, AS | 1 |
| Chiu, GS | 1 |
| Lawson, MA | 1 |
| Gainey, SJ | 1 |
| York, JM | 1 |
| Meling, DD | 1 |
| Martin, SA | 1 |
| Kwakwa, KA | 1 |
| Newman, AF | 1 |
| Woods, JA | 1 |
| Kelley, KW | 1 |
| Wang, Y | 1 |
| Miller, MJ | 1 |
| Freund, GG | 1 |
| Na, KS | 1 |
| Lee, SI | 1 |
| Hong, SD | 1 |
| Kim, JH | 1 |
| Shim, SH | 1 |
| Choi, J | 1 |
| Yang, J | 1 |
| Lee, MS | 1 |
| Joung, YS | 1 |
| Kim, EJ | 1 |
| Park, JH | 1 |
| Fosi, T | 1 |
| Lax-Pericall, MT | 1 |
| Scott, RC | 1 |
| Neville, BG | 1 |
| Aylett, SE | 1 |
| Reddick, WE | 3 |
| Taghipour, DJ | 1 |
| Glass, JO | 1 |
| Ashford, J | 2 |
| Xiong, X | 3 |
| Wu, S | 2 |
| Bonner, M | 2 |
| Khan, RB | 2 |
| Conklin, HM | 2 |
| Vaquerizo-Madrid, J | 1 |
| Ramírez-Arenas, M | 1 |
| Cáceres-Marzal, C | 1 |
| Arias-Castro, S | 1 |
| Fernández-Carbonero, M | 1 |
| Valverde-Palomares, R | 1 |
| Einecke, U | 1 |
| Peadon, E | 1 |
| Rhys-Jones, B | 1 |
| Bower, C | 1 |
| Elliott, EJ | 1 |
| Helton, S | 1 |
| Mulhern, RK | 2 |
| Brown, R | 1 |
| Jasper, BW | 1 |
| Breuer, D | 1 |
| Wolff Metternich, T | 1 |
| Döpfner, M | 2 |
| Amos-Kroohs, RM | 1 |
| Williams, MT | 1 |
| Vorhees, CV | 1 |
| Idiazábal-Alecha, MA | 1 |
| Kosno, M | 1 |
| Williamson, D | 1 |
| Murray, DW | 1 |
| Damaraju, CV | 1 |
| Ascher, S | 1 |
| Starr, HL | 1 |
| Mautner, VF | 1 |
| Taylor, E | 1 |
| Sergeant, J | 1 |
| Asherson, P | 1 |
| Banaschewski, T | 1 |
| Buitelaar, J | 1 |
| Coghill, D | 1 |
| Danckaerts, M | 1 |
| Rothenberger, A | 1 |
| Sonuga-Barke, E | 1 |
| Steinhausen, HC | 1 |
| Zuddas, A | 1 |
| Gross-Tsur, V | 1 |
| Joseph, A | 1 |
| Shalev, RS | 1 |
| Thompson, MJ | 1 |
| Brooke, XM | 1 |
| West, CA | 1 |
| Johnson, HR | 1 |
| Bumby, EJ | 1 |
| Brodrick, P | 1 |
| Pepe, G | 1 |
| Laver-Bradbury, C | 1 |
| Scott, N | 1 |
| Quinn, PO | 1 |
| Griggins, C | 1 |
| Sabini, J | 1 |
| Monterosso, J | 1 |
| Gureasko-Moore, S | 1 |
| Dupaul, GJ | 1 |
| White, GP | 1 |
| Grizenko, N | 2 |
| Bhat, M | 1 |
| Schwartz, G | 1 |
| Ter-Stepanian, M | 1 |
| Joober, R | 1 |
| Brook, U | 1 |
| Boaz, M | 1 |
| Prabhuswamy, M | 1 |
| Srinath, S | 1 |
| Girimaji, S | 1 |
| Seshadri, S | 1 |
| Salgado, JV | 1 |
| Costa-Silva, M | 1 |
| Malloy-Diniz, LF | 1 |
| Siqueira, JM | 1 |
| Teixeira, AL | 1 |
| Gadow, KD | 1 |
| Ackerman, PT | 2 |
| Holcomb, PJ | 2 |
| Dykman, RA | 2 |
| McCray, DS | 1 |
| Myers, GJ | 1 |
| Libb, JW | 1 |
| Clampit, MK | 1 |
| de Quirós, GB | 1 |
| Kinsbourne, M | 3 |
| Palmer, RL | 1 |
| Rufo, DT | 1 |
| Walkup, JT | 1 |
| Scahill, LD | 1 |
| Riddle, MA | 1 |
| Sayegh, L | 1 |
| Papineau, D | 1 |
| Rubinstein, S | 1 |
| Silver, LB | 3 |
| Licamele, WL | 1 |
| Rapport, MD | 1 |
| Loo, S | 1 |
| Isaacs, P | 1 |
| Goya, S | 1 |
| Denney, C | 1 |
| Scanlan, S | 1 |
| Shaywitz, BA | 1 |
| Fletcher, JM | 1 |
| Shaywitz, SE | 1 |
| Detterman, DK | 1 |
| Thompson, LA | 1 |
| Thompson, SJ | 1 |
| Leigh, L | 1 |
| Christensen, R | 1 |
| Kun, LE | 1 |
| Heideman, RL | 1 |
| Gajjar, A | 1 |
| Merchant, T | 1 |
| Pui, CH | 1 |
| Hudson, MM | 1 |
| Lambert, NM | 1 |
| Windmiller, M | 1 |
| Sandoval, J | 1 |
| Moore, B | 1 |
| Gabrys, JB | 1 |
| Seals, JR | 1 |
| Bellak, L | 1 |
| Gittleman-Klein, R | 1 |
| Klein, DF | 1 |
| Rapaport, HG | 1 |
| Flint, SH | 1 |
| Lewis, JA | 1 |
| Young, R | 1 |
| Rie, HE | 1 |
| Stein, MT | 1 |
| Ayllon, T | 1 |
| Layman, D | 1 |
| Kandel, HJ | 1 |
| Sulzbacher, SI | 1 |
| Levy, HB | 1 |
| Levinson, HN | 1 |
| Swanson, JM | 2 |
| Cantwell, D | 1 |
| Lerner, M | 1 |
| McBurnett, K | 1 |
| Hanna, G | 1 |
| Dalby, JT | 1 |
| Perry, HC | 1 |
| Collings, SJ | 1 |
| Famularo, R | 1 |
| Fenton, T | 1 |
| Faigel, HC | 1 |
| Sroufe, LA | 2 |
| Stewart, MA | 1 |
| Millichap, JG | 3 |
| Vogel, MJ | 1 |
| Satterfield, JH | 1 |
| Cantwell, DP | 1 |
| Satterfield, BT | 1 |
| Erenberg, G | 1 |
| Sonies, BC | 1 |
| West, WD | 1 |
| Wright, FS | 1 |
| Wender, PH | 1 |
| Sprague, RL | 1 |
| Sleator, EK | 1 |
| Omenn, GS | 1 |
| Spring, C | 1 |
| Greenberg, L | 1 |
| Scott, J | 1 |
| Hopwood, J | 1 |
| Machanick, S | 1 |
| Friedman, R | 1 |
| Dale, EP | 1 |
| Wagner, JH | 1 |
| Fritz, JJ | 1 |
| Peters, JE | 1 |
| Fowler, GW | 1 |
| Knights, RM | 1 |
| Hinton, GG | 1 |
| McCabe, ER | 1 |
| McCabe, L | 1 |
| Browder, JA | 1 |
| Schwartz, ML | 1 |
| Pizzo, SV | 1 |
| McKee, PA | 1 |
| Conners, CK | 1 |
| Oettinger, L | 1 |
| Aymat, F | 1 |
| Sturgis, LH | 1 |
| Larsen, KW | 1 |
| Egan, RA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Learning Skill After OROS Methylphenidate Treatment in Adolescents With Attention-Deficit/Hyperactivity Disorder: A 12-week, Multi-center, Open-label Study[NCT01060150] | Phase 4 | 115 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Single-blind, Randomised, Sham Controlled, Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of BGX-3006 (tPCS) on Paediatric ADHD Participants.[NCT02323633] | Phase 2 | 48 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 2.14 |
"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher scores indicate worsening." (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 2.81 |
The K-ARS is a rating scale that is used for the ADHD diagnosis and the assessment of treatment efficacy and comprises 18 items in total on the basis of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV), each item being rated from 0-3 points. The total score ranges from 0-54 with 0=normal and 54=severe condition. (NCT01060150)
Timeframe: Week 12
| Intervention | Units on a scale (Mean) |
|---|---|
| OROS Methylphenidate HCl | 11.78 |
The LST measures learning ability of student. This scale is composed of 7 sections: self control, participation, task accomplishment, reading, writing, test taking and information processing. It consists of 70 items for middle school student (age 13-15 years) and 80 items for high school student (age 16-18 years). Each item is rated on a 5-point Likert scale ranging from 1 (never) to 5 (always). The total score range is 70-350 for middle school version and 80-400 for high school version where higher score indicates better ability for learning. In result analysis, each sub-score and total score was converted to T-score for normalization. The score range of T-score is from 1 to 100 with a mean of 50. Higher score indicates better ability for learning. (NCT01060150)
Timeframe: Week 12
| Intervention | T-score (Mean) |
|---|---|
| OROS Methylphenidate HCl | 49.61 |
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/commission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention. The total value for both, omission errors and commission errors, ranges from 0-100 errors where high value indicates worsening attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Errors (Mean) | |||
|---|---|---|---|---|
| Omission errors: Baseline | Omission errors: Week 12 | Commission errors: Baseline | Commission errors: Week 12 | |
| OROS Methylphenidate HCl | 58.88 | 57.40 | 62.98 | 51.70 |
The ADS is composed of 4 factors: omission/missing frequency to measure attention dispersibility; false alarm/comission frequency to measure impulse; mean response/reaction time to measure the speed of task processing; and the response variability/standard deviation of response time to measure the consistency of attention. The score range for both, reaction time and response variability, is 0-100. High score indicates worsening attention. If one or over factor's score is over 65 point, the participant is resulted in having attention deficit. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on scale (Mean) | |||
|---|---|---|---|---|
| Reaction time average: Baseline | Reaction time average: Week 12 | Response variability: Baseline | Response variability: Week 12 | |
| OROS Methylphenidate HCl | 54.32 | 49.73 | 85.77 | 59.42 |
This test measures the executive function of the frontal lobe and is consisted of examinations of category/meaning fluency and letter/phoneme fluency. It consisted of three 60 second word generation trials in which the participant orally generates as many words as possible that begin with target letters F, A and S. Dependent variables included total number of acceptable words generated for each target letter and total number of words generated across all three letter trials. Total score was calculated as sum of acceptable words generated, with higher scores indicating better verbal fluency. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Words (Mean) | |||
|---|---|---|---|---|
| Category/semantic: Baseline | Category/semantic: Week 12 | Letter/phenomic: Baseline | Letter/phenomic: Week 12 | |
| OROS Methylphenidate HCl | 29.71 | 30.62 | 28.71 | 33.78 |
Each participant individually was given a sequence of numbers, with the sequence becoming progressively longer, to repeat the digits in the same sequence, either forwards or backwards. Each sequence length was attempted twice. The test was complete after failure on both trials of any sequence length. 1 point was awarded if the participant passed only 1 trial of a sequence length. 0 points were given if the participant failed both trials. Total score range was 0-16 (forwards) and 0-14 (backwards). A higher score was indicative of better recall and attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Forward: Baseline | Forward: Week 12 | Backward: Baseline | Backward: Week 12 | |
| OROS Methylphenidate HCl | 11.19 | 11.56 | 7.09 | 7.32 |
In FW test, a participant shows memory of a demonstrated visual pattern using a 8x11 inch plastic template containing 9 asymmetrically located holes. The examiner models a given sequence of holes and asks the participant to imitate the sequence by placing his/her finger through the same holes in the correct order. The total number of correct sequences constitutes the total score which ranges from 0-24 (forward FW) and 0-28 (backward FW) with higher score indicating a more favorable health state. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |||
|---|---|---|---|---|
| Forward FW: Baseline | Forward FW: Week 12 | Backward FW: Baseline | Backward FW: Week 12 | |
| OROS Methylphenidate HCl | 18.42 | 19.09 | 15.59 | 17.36 |
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution). In simple execution, participants have to read the written color names of the words independent of the color of the ink. In middle execution, participants have to read words written in black letters. In interfering experiment, participants have to say the color of the letters independent of the written word. The total value ranges from 0-24 errors for each execution where high value indicates worsening attention. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Errors (Mean) | |||||
|---|---|---|---|---|---|---|
| Simple execution false reaction: Baseline | Simple execution false reaction: Week 12 | Middle execution false reaction: Baseline | Middle execution false reaction: Week 12 | Interfering execution false reaction: Baseline | Interfering execution false reaction: Week 12 | |
| OROS Methylphenidate HCl | 0.4 | 0.16 | 0.3 | 0.2 | 1.04 | 0.84 |
This test consists of 3 trials: color trial (simple execution), word trial (middle execution) and word-color interference trial (interfering execution). In simple execution, participants have to read the written color names of the words independent of the color of the ink. In middle execution, participants have to read words written in black letters. In interfering experiment, participants have to say the color of the letters independent of the written word. This test estimates spending time for execution. High spending time indicates low ability of suppression of automation. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Seconds (Mean) | |||||
|---|---|---|---|---|---|---|
| Simple execution time: Baseline | Simple execution time: Week 12 | Middle execution time: Baseline | Middle execution time: Week 12 | Interfering execution time: Baseline | Interfering execution time: Week 12 | |
| OROS Methylphenidate HCl | 14.78 | 13.64 | 15.88 | 15.04 | 22.12 | 19.72 |
Ratio interference is calculated by dividing simple execution time by interfering execution time. The score range is 0-1. Higher value indicates better ability of suppression of automation. (NCT01060150)
Timeframe: Baseline and Week 12
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| OROS Methylphenidate HCl | 0.70 | 0.72 |
18 reviews available for methylphenidate and Learning Disabilities
| Article | Year |
|---|---|
Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2013 |
Systematic review of interventions for children with Fetal Alcohol Spectrum Disorders.
Topics: Alcohol-Induced Disorders, Nervous System; Antipsychotic Agents; Attention Deficit Disorder with Hyp | 2009 |
[Attention deficit hyperactivity disorder and epilepsy in childhood].
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Causality; Child; Child, | 2012 |
Effects of stimulant drugs on academic performance in hyperactive and learning disabled children.
Topics: Achievement; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimul | 1983 |
Disruptive behavior, hyperactivity, and learning disabilities in children with Tourette's syndrome.
Topics: Adolescent; Antidepressive Agents, Tricyclic; Attention Deficit Disorder with Hyperactivity; Child; | 1995 |
Attention-deficit/hyperactivity disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Humans; Lea | 1997 |
What is so special about special education?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Combined Modalit | 1997 |
Hyperactive children and the efficacy of psychoactive drugs as a treatment intervention.
Topics: Amphetamines; Central Nervous System Stimulants; Child Behavior; Chlordiazepoxide; Chlorpromazine; C | 1976 |
Acceptable and controversial approaches to treating the child with learning disabilities.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Attention; Child; | 1975 |
MBD: advanced in understanding many bothersome dilemmas.
Topics: Adolescent; Adult; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool | 1976 |
Effects of stimulant medication on learning in children with ADHD.
Topics: Achievement; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetamine; Humans; Learni | 1991 |
Treating problem children with stimulant drugs.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants | 1973 |
Drug therapy in minimal brain dysfunction: a commentary.
Topics: Amphetamine; Anticonvulsants; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; | 1972 |
Minimal brain dysfunction in children. Diagnosis and management.
Topics: Abnormalities, Multiple; Affective Symptoms; Age Factors; Amphetamine; Attention; Attention Deficit | 1973 |
Effects of psychopharmacologic agents on learning disorders.
Topics: Achievement; Animals; Child; Child Behavior; Child Psychiatry; Dextroamphetamine; Dose-Response Rela | 1973 |
Genetic issues in the syndrome of minimal brain dysfunction.
Topics: Attention Deficit Disorder with Hyperactivity; Dextroamphetamine; Diseases in Twins; Female; Humans; | 1973 |
Treatment of "minimal brain dysfunction" syndromes. Selection of drugs for children with hyperactivity and learning disabilities.
Topics: Amphetamine; Anticonvulsants; Brain Damage, Chronic; Child; Chlordiazepoxide; Chlorpromazine; Clinic | 1967 |
The neurologic learning disability syndrome.
Topics: Anorexia Nervosa; Anxiety; Attention; Attention Deficit Disorder with Hyperactivity; Brain Damage, C | 1971 |
16 trials available for methylphenidate and Learning Disabilities
| Article | Year |
|---|---|
Effect of osmotic-release oral system methylphenidate on learning skills in adolescents with attention-deficit/hyperactivity disorder: an open-label study.
Topics: Administration, Oral; Adolescent; Anorexia; Attention Deficit Disorder with Hyperactivity; Child; De | 2013 |
Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: Adolescent; Attention; Brain Neoplasms; Child; Cognition; Comorbidity; Cross-Over Studies; Dopamine | 2010 |
Methylphenidate in children with ADHD with or without learning disability.
Topics: Administration, Oral; Attention; Attention Deficit Disorder with Hyperactivity; Central Nervous Syst | 2014 |
Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cross-Over | 2006 |
Effects of reward and methylphenidate on heart rate response morphology of augmenting and reducing children.
Topics: Attention Deficit Disorder with Hyperactivity; Auditory Perception; Electroencephalography; Evoked P | 1984 |
Methylphenidate effects on cognitive style and reaction time in four groups of children.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Cognition Disorders; Dose-Response | 1982 |
Attention deficit disorder in children: three clinical variants.
Topics: Adolescent; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorder | 1994 |
Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention-deficit/hyperactivity disorder.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Central Nervous System S | 1996 |
Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer.
Topics: Administration, Oral; Adolescent; Attention; Brain Neoplasms; Child; Cognition Disorders; Double-Bli | 2001 |
Methylphenidate effects in learning disabilities. Psychometric changes.
Topics: Adolescent; Child; Family Characteristics; Female; Humans; Learning Disabilities; Male; Methylphenid | 1976 |
Deanol and methylphenidate in minimal brain dysfunction.
Topics: Analysis of Variance; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic | 1975 |
Self-paced learning in children with attention deficit disorder with hyperactivity.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Clinical Trials as Topic; Double-Bl | 1989 |
Anticipatory heart rate deceleration and reaction time in children with and without referral for learning disability.
Topics: Attention; Attention Deficit Disorder with Hyperactivity; Child; Child Development; Clinical Trials | 1973 |
Treatment of "minimal brain dysfunction" syndromes. Selection of drugs for children with hyperactivity and learning disabilities.
Topics: Amphetamine; Anticonvulsants; Brain Damage, Chronic; Child; Chlordiazepoxide; Chlorpromazine; Clinic | 1967 |
The effects of methylphenidate (Ritalin) on the motor skills and behavior of children with learning problems.
Topics: Adolescent; Blood Pressure; Body Weight; Child; Child Psychiatry; Clinical Trials as Topic; Electroe | 1969 |
Hyperkinetic behavior and learning disorders. 3. Battery of neuropsychological tests in controlled trial of methylphenidate.
Topics: Adolescent; Child; Child Behavior Disorders; Child, Preschool; Female; Humans; Hydrochloric Acid; In | 1968 |
48 other studies available for methylphenidate and Learning Disabilities
| Article | Year |
|---|---|
Narcolepsy-cataplexy and psychosis: a case study.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compound | 2017 |
Methylphenidate prevents high-fat diet (HFD)-induced learning/memory impairment in juvenile mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Anxiety; Blood Glucose; Body Weight; | 2013 |
Prognostic factors that increase the risk for reduced white matter volumes and deficits in attention and learning for survivors of childhood cancers.
Topics: Age Factors; Antineoplastic Agents; Attention; Attention Deficit Disorder with Hyperactivity; Brain; | 2014 |
[Non-verbal learning disorders: a clinical study and pharmacological treatment].
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2009 |
[Without treatment the crash threatens].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivi | 2009 |
[The assessment of Attention Deficit Hyperactivity Disorder (ADHD) by teacher ratings - validity and reliability of the FBB-HKS].
Topics: Adolescent; Affective Symptoms; Attention Deficit Disorder with Hyperactivity; Central Nervous Syste | 2009 |
Neonatal methylphenidate does not impair adult spatial learning in the Morris water maze in rats.
Topics: Aging; Animals; Animals, Newborn; Central Nervous System Stimulants; Disease Models, Animal; Female; | 2011 |
[Stimulant drugs in neurofibromatosis type 1 and attention deficit disorder].
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2002 |
European clinical guidelines for hyperkinetic disorder -- first upgrade.
Topics: Alleles; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Ch | 2004 |
Hallucinations during methylphenidate therapy.
Topics: Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; | 2004 |
Profiles, co-morbidity and their relationship to treatment of 191 children with AD/HD and their families.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; | 2004 |
Treating adolescent girls and women with ADHD: gender-specific issues.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Anxiety Disorders; Attention Deficit Disorder with Hype | 2005 |
Dosing dilemmas: are you rich and white or poor and black?
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Black or African American; Central Nervou | 2005 |
Judgments of the fairness of using performance enhancing drugs.
Topics: Analysis of Variance; Attention; Attention Deficit Disorder with Hyperactivity; Attitude; Biomedical | 2005 |
The effects of self-management in general education classrooms on the organizational skills of adolescents with ADHD.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Combined Modality Thera | 2006 |
Adolescents with attention deficit and hyperactivity disorder/learning disability and their proneness to accidents.
Topics: Accident Proneness; Accidents; Adolescent; Attention Deficit Disorder with Hyperactivity; Central Ne | 2006 |
Methylphenidate and hypertension.
Topics: Adolescent; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyp | 2006 |
Prefrontal cognitive dysfunction following brainstem lesion.
Topics: Adolescent; Adult; Astrocytoma; Attention; Brain Stem Neoplasms; Central Nervous System Stimulants; | 2007 |
The physician's role in learning disability.
Topics: Adult; Attention Deficit Disorder with Hyperactivity; Child; Environment; Female; Humans; Learning D | 1982 |
Residual attentional deficits in adolescents.
Topics: Achievement; Adolescent; Attention; Humans; Learning Disabilities; Male; Methylphenidate | 1981 |
Predicting outcome in a multimodal day treatment program for children with severe behaviour problems.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Child, P | 1994 |
Clonidine for stimulant-related sleep problems.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Dextroamphetamine; Drug Therapy, Co | 1994 |
Methylphenidate effect on attentional and cognitive behavior in six- through twelve-year-old males.
Topics: Attention; Child; Cognition; Drug Evaluation; Humans; Intelligence Tests; Learning Disabilities; Mal | 1977 |
A possible subgroup of the schizophrenic syndrome and implications for treatment.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Diazepam; Dominance, Cerebral; Dys | 1976 |
Is there a relationship between allergy and learning disabilities?
Topics: Child; Humans; Hyperkinesis; Hypersensitivity; Learning Disabilities; Male; Methylphenidate; School | 1976 |
Hyperactivity in children.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Reactive Disorders; Dextroamphetamine; D | 1975 |
Minimal brain dysfunction: A note of caution in management.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Humans; Learning Disabilities; Methylphenidate | 1975 |
A behavioral-educational alternative to drug control of hyperactive children.
Topics: Achievement; Behavior Therapy; Child; Female; Humans; Hyperkinesis; Learning Disabilities; Male; Met | 1975 |
The learning-disabled or hyperactive child: diagnosis and treatment.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dextroamphetamine; H | 1975 |
Minimal brain dysfunction/specific learning disability: a clinical approach for the primary physician.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child Behavior Disorders; Dextroamphetamine; F | 1976 |
Dramatic favorable responses of children with learning disabilities or dyslexia and attention deficit disorder to antimotion sickness medications: four case reports.
Topics: Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Cyclizine; | 1991 |
The use of stimulant medication in the treatment of childhood behavioural and learning disorders. A descriptive survey.
Topics: Adolescent; Child Behavior Disorders; Humans; Learning Disabilities; Male; Methylphenidate | 1988 |
The effect of methylphenidate on school grades in children with attention deficit disorder without hyperactivity: a preliminary report.
Topics: Achievement; Attention; Child; Educational Measurement; Female; Humans; Learning Disabilities; Male; | 1987 |
The adolescent with a learning problem. The need for insight.
Topics: Adolescent; Age Factors; Attention Deficit Disorder with Hyperactivity; Community Mental Health Serv | 1973 |
School problems: diagnosis and treatment.
Topics: Agnosia; Amphetamine; Anxiety; Child; Child, Preschool; Cognition Disorders; Developmental Disabilit | 1973 |
Drugs in the management of learning and behavior disorders in school children.
Topics: Amphetamine; Anticonvulsants; Child; Child Behavior Disorders; Humans; Learning Disabilities; Methyl | 1974 |
Learning disability.
Topics: Ascorbic Acid; Child; Female; Humans; Learning Disabilities; Male; Methylphenidate; Niacinamide | 1973 |
Pathophysiology of the hyperactive child syndrome.
Topics: Animals; Arousal; Attention Deficit Disorder with Hyperactivity; Auditory Perception; Brain; Child; | 1974 |
Reaction time and effect of Ritalin on children with learning problems.
Topics: Attention; Child; Discrimination, Psychological; Dyslexia; Female; Form Perception; Humans; Hyperkin | 1973 |
Learning disabilities in childhood.
Topics: Child; Child, Preschool; Electroencephalography; Female; Humans; Hyperkinesis; Learning Disabilities | 1973 |
A long-term comparison of two treatment regimens for minimal brain dysfunction. Drug therapy versus combined therapy.
Topics: Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Counseling; Dextroamphetamin | 1973 |
Reversal-shift behavior in children with specific learning disabilities.
Topics: Attention; Child; Color Perception; Dextroamphetamine; Discrimination Learning; Education, Special; | 1974 |
Minimal brain dysfunctions in children.
Topics: Amphetamine; Attention; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Comm | 1974 |
Dissociation of learning on stimulant-drug therapy.
Topics: Amphetamine; Animals; Antidepressive Agents; Child; Dextroamphetamine; Humans; Hyperkinesis; Learnin | 1972 |
Appropriate use of psychic drugs in school children.
Topics: Adolescent; Antidepressive Agents; Child; Child Behavior Disorders; Humans; Intellectual Disability; | 1972 |
Minimal brain dysfunction and methylphenidate.
Topics: Advertising; Attention Deficit Disorder with Hyperactivity; Brain Damage, Chronic; Brain Diseases; C | 1971 |
Review of stimulant drugs in learning and behavior disorders.
Topics: Aggression; Amphetamine; Child; Child Behavior Disorders; Dextroamphetamine; Humans; Hyperkinesis; L | 1971 |
Learning disorders, hyperkinesis, and the use of drugs in children.
Topics: Amphetamine; Child; Humans; Hyperkinesis; Learning Disabilities; Methylphenidate; Psychological Test | 1971 |